CDXS - Codexis Inc Stock Price, Fair Value and News

2.80USD-0.10 (-3.45%)Market Closed

Market Summary

USD2.80-0.10

Market Closed

-3.45%

CDXS Stock Price

View Fullscreen

CDXS RSI Chart

CDXS Valuation

Market Cap

203.9M

Price/Earnings (Trailing)

-2.67

Price/Sales (Trailing)

2.91

EV/EBITDA

-1.97

Price/Free Cashflow

-3.57

CDXS Price/Sales (Trailing)

CDXS Profitability

EBT Margin

-108.59%

Return on Equity

-88.02%

Return on Assets

-55.83%

Free Cashflow Yield

-27.99%

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

70.1M

Rev. Growth (Yr)

-12.55%

Rev. Growth (Qtr)

186.31%

CDXS Earnings

Earnings (TTM)

-76.2M

Earnings Growth (Yr)

42.94%

Earnings Growth (Qtr)

79.4%

Breaking Down CDXS Revenue

Last 7 days

5.9%

Last 30 days

-16.2%

Last 90 days

7.0%

Trailing 12 Months

-30.7%

How does CDXS drawdown profile look like?

CDXS Financial Health

Current Ratio

2.61

Debt/Equity

Debt/Cashflow

-431.46

CDXS Investor Care

Shares Dilution (1Y)

6.61%

Diluted EPS (TTM)

-1.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	116.2M	99.1M	74.0M	70.1M
2022	122.1M	135.0M	132.7M	138.6M
2021	72.4M	82.9M	101.3M	104.8M
2020	67.5M	70.2M	66.7M	69.1M
2019	62.1M	60.9M	65.9M	68.5M
2018	56.1M	59.3M	66.2M	60.6M
2017	48.8M	43.2M	38.3M	50.0M
2016	43.0M	53.0M	50.5M	48.8M
2015	35.0M	34.5M	44.4M	41.8M
2014	27.5M	27.1M	30.6M	35.3M
2013	68.6M	52.7M	30.3M	31.9M
2012	124.0M	120.8M	113.9M	88.3M
2011	112.4M	114.0M	120.2M	123.9M
2010	0	91.0M	99.0M	107.1M
2009	0	0	0	82.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Codexis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 01, 2024	ryali sriram	acquired	-	-	52,350	chief financial officer
Jan 01, 2024	dilly stephen george	acquired	-	-	143,425	see remarks
Jan 01, 2024	fitzgerald margaret nell	acquired	-	-	52,350	see remarks
Jan 01, 2024	norrett kevin	acquired	-	-	52,350	chief operating officer
Nov 15, 2023	dorgan byron l	sold	-42,168	2.1084	-20,000	-
Sep 11, 2023	norrett kevin	bought	15,479	1.7199	9,000	chief operating officer
Sep 08, 2023	ryali sriram	bought	19,856	1.7044	11,650	chief financial officer
Sep 08, 2023	dilly stephen george	bought	100,952	1.7263	58,479	see remarks
Sep 08, 2023	fitzgerald margaret nell	bought	20,064	1.6955	11,834	see remarks
Jun 13, 2023	smith david v	acquired	-	-	34,602	-

Which funds bought or sold CDXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	273	1,222	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-65.89	-12,000	7,000	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	170,784	1,354,620	0.11%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	39,875	104,844	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-91.09	-127,339	14,452	-%
Apr 17, 2024	Annapolis Financial Services, LLC	sold off	-100	-15,250	-	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	1.00	11.00	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	967	3,923	-%
Apr 05, 2024	CWM, LLC	added	33.23	3,000	8,000	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-176	-	-%

Are Funds Buying or Selling CDXS?

Are funds buying CDXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDXS

No. of Funds

Unveiling Codexis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	6.6%	4,592,903	SC 13G/A
Feb 13, 2024	vanguard group inc	5.91%	4,128,428	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 24, 2024	blackrock inc.	10.3%	7,196,414	SC 13G/A
Jan 08, 2024	baillie gifford & co	4.90%	3,419,093	SC 13G/A
Aug 08, 2023	blackrock inc.	10.4%	6,932,344	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	6.8%	4,487,782	SC 13G/A
Feb 14, 2023	casdin capital, llc	0%	0	SC 13G/A
Feb 10, 2023	ark investment management llc	6.00%	3,941,985	SC 13G/A
Feb 09, 2023	vanguard group inc	5.54%	3,642,208	SC 13G/A

Recent SEC filings of Codexis Inc

View All Filings

Date Filed	Form Type	Document
Mar 06, 2024	8-K	Current Report
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 16, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	8-K	Current Report
Feb 09, 2024	SC 13G	Major Ownership Report
Feb 09, 2024	8-K	Current Report
Jan 24, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Codexis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Codexis Inc News

Latest updates

Codexis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	186.3%	26,561,000	9,277,000	21,323,000	12,982,000	30,374,500	34,470,000	38,406,000	35,340,000	24,500,500	36,769,000	25,453,000	18,032,000	21,033,500	18,385,000	14,967,000	14,670,000	18,650,000	21,906,000	12,319,000	15,583,000	16,068,000
Costs and Expenses	-36.4%	26,279,500	41,337,000	33,949,000	36,647,000	43,624,500	45,106,000	41,015,000	43,726,000	34,886,000	35,439,000	29,939,000	27,187,000	24,956,500	24,449,000	21,074,000	22,497,000	19,596,500	21,647,000	18,942,000	20,822,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,647,000	18,942,000	20,822,000	16,712,000
S&GA Expenses	-1.0%	12,184,000	12,302,000	13,365,000	15,399,000	12,312,500	13,499,000	10,656,000	15,705,000	11,723,000	13,407,000	12,795,000	11,398,000	8,741,500	8,797,000	8,522,000	8,989,000	7,322,000	7,869,000	7,896,000	8,415,000	6,806,000
R&D Expenses	-17.8%	11,234,000	13,662,000	17,334,000	16,655,000	19,689,000	21,821,000	19,089,000	19,500,000	16,357,000	15,165,000	12,826,000	11,571,000	10,355,000	12,010,000	10,853,000	10,967,000	8,872,500	8,711,000	8,274,000	8,016,000	7,513,500
EBITDA Margin	1.6%	-1.01	-1.02	-0.51	-0.36	-0.20	-0.20	-0.11	-0.14	-0.17	-0.12	-0.25	-0.32	-	-	-	-	-	-	-	-	-
Interest Expenses	-11.1%	16,000	18,000	3,000	7,000	12,000	10,000	7,000	5,000	8,000	3,000	-	3,000	37,000	11,000	-	4,000	33,000	7,000	-13,000	22,000	23,000
Income Taxes	288.9%	35,000	9,000	9,000	16,000	151,000	8,000	108,000	9,000	68,500	110,000	8,000	2,000	8,000	19,000	307,000	5,000	5,000	-7,000	16,000	3,000	-25,500
Earnings Before Taxes	79.5%	-7,157,000	-34,899,000	-11,514,000	-22,601,000	-12,453,000	-9,984,000	-2,532,000	-8,347,000	-10,121,500	2,354,000	-4,257,000	-9,066,000	-3,912,000	-6,075,000	-6,037,000	-7,647,000	-630,000	336,000	-6,491,000	-5,133,000	-486,500
EBT Margin	1.4%	-1.09	-1.10	-0.57	-0.41	-0.24	-0.23	-0.14	-0.17	-0.20	-0.15	-0.28	-0.35	-	-	-	-	-	-	-	-	-
Net Income	79.4%	-7,192,000	-34,908,000	-11,523,000	-22,617,000	-12,604,000	-9,992,000	-2,640,000	-8,356,000	-10,190,000	2,244,000	-4,265,000	-9,068,000	-3,920,000	-6,094,000	-6,344,000	-7,652,000	-635,000	343,000	-6,507,000	-5,136,000	-461,000
Net Income Margin	1.6%	-1.09	-1.10	-0.57	-0.41	-0.24	-0.23	-0.14	-0.17	-0.20	-0.15	-0.28	-0.35	-	-	-	-	-	-	-	-	-
Free Cashflow	37.2%	-10,657,000	-16,980,000	-17,668,000	-11,751,000	4,950,000	18,424,000	-4,122,000	-16,275,000	-4,820,000	-4,196,000	-10,089,000	-8,990,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.6%	137	154	207	218	250	235	235	235	246	228	212	212	222	138	142	149	149	146	147	101	79.00
Current Assets	-9.3%	93.00	103	120	130	163	146	145	145	162	174	172	174	184	103	106	115	114	110	110	64.00	68.00
Cash Equivalents	-12.7%	65.00	75.00	92.00	103	114	109	90.00	94.00	117	119	130	140	151	72.00	76.00	87.00	92.00	92.00	93.00	47.00	54.00
Inventory	16.5%	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00	1.00
Net PPE	1.3%	15.00	15.00	23.00	24.00	23.00	23.00	24.00	23.00	21.00	16.00	11.00	10.00	10.00	7.00	7.00	7.00	6.00	6.00	5.00	5.00	5.00
Goodwill	0%	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	-20.7%	50.00	63.00	83.00	92.00	106	81.00	76.00	77.00	82.00	58.00	50.00	48.00	52.00	47.00	47.00	50.00	44.00	44.00	48.00	50.00	23.00
Current Liabilities	-6.7%	36.00	38.00	36.00	38.00	49.00	32.00	30.00	29.00	33.00	33.00	24.00	23.00	25.00	20.00	19.00	22.00	15.00	15.00	17.00	19.00	18.00
Shareholder's Equity	-5.3%	87.00	92.00	124	126	145	154	159	159	164	169	163	164	170	91.00	95.00	99.00	106	103	99.00	51.00	56.00
Retained Earnings	-1.5%	-497	-490	-455	-443	-421	-408	-398	-396	-387	-377	-379	-375	-366	-362	-356	-350	-342	-341	-342	-335	-330
Additional Paid-In Capital	0.4%	584	582	580	570	566	563	558	555	552	547	543	539	537	453	451	449	448	444	441	387	387
Shares Outstanding	0.1%	70.00	70.00	70.00	67.00	66.00	65.00	65.00	65.00	65.00	65.00	64.00	64.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	122	-	-	-	384	-	-	-	738	-	-	-	656	-	-	-	1,070	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	32.3%	-11,037	-16,302	-16,087	-9,212	4,917	19,734	-2,181	-11,186	660	-192	-8,295	-6,440	-1,492	-3,474	-10,073	-1,425	-3,661	-990	-5,058	-2,851	-720
Share Based Compensation	-5.3%	2,163	2,283	2,716	2,809	2,931	4,531	3,231	3,838	3,046	3,016	2,844	2,687	1,636	1,984	1,939	2,169	1,160	1,732	1,988	2,063	1,682
Cashflow From Investing	199.7%	1,104	-1,107	-1,571	-3,284	33.00	-1,309	-2,220	-10,082	-5,480	-10,997	-2,412	-2,533	-2,488	-770	-1,729	-761	-414	-1,994	-812	-445	-693
Cashflow From Financing	100.0%	-	-108	6,923	1,352	339	133	233	-1,280	2,426	868	456	17.00	81,586	125	116	-1,019	2,422	1,688	51,933	-2,082	251

CDXS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 70,143	$ 138,590	$ 104,754
Costs and operating expenses:
Cost of product revenue	12,809	38,033	22,209
Research and development	58,885	80,099	55,919
Selling, general and administrative	53,250	52,172	49,323
Restructuring charges	3,284	3,167	0
Asset impairment and other charges	9,984	0	0
Total costs and operating expenses	138,212	173,471	127,451
Loss from operations	(68,069)	(34,881)	(22,697)
Interest income	4,172	1,441	459
Other income (expense), net ($0, $208 and $983 from a related party)	(12,274)	124	1,148
Loss before income taxes	(76,171)	(33,316)	(21,090)
Provision for income taxes	69	276	189
Net loss	$ (76,240)	$ (33,592)	$ (21,279)
Net loss per share, basic (in dollars per share)	$ (1.12)	$ (0.51)	$ (0.33)
Net loss per share, diluted (in dollars per share)	$ (1.12)	$ (0.51)	$ (0.33)
Weighted average common stock shares used in computing net loss per share, basic (in shares)	68,131	65,344	64,568
Weighted average common stock shares used in computing net loss per share, diluted (in shares)	68,131	65,344	64,568
Product revenue ($0, $514 and $0 from a related party)
Revenues:
Total revenues	$ 42,906	$ 116,676	$ 70,657
Research and development revenue ($0, $1,245 and $1,955 from a related party)
Revenues:
Total revenues	$ 27,237	$ 21,914	$ 34,097

CDXS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 65,116	$ 113,984
Restricted cash, current	519	521
Financial assets:
Accounts receivable	10,036	31,904
Contract assets	815	2,116
Unbilled receivables	9,142
Total financial assets	19,993	41,036
Less: allowances	(65)	(163)
Total financial assets, net	19,928	40,873
Inventories	2,685	2,029
Prepaid expenses and other current assets	5,218	5,487
Total current assets	93,466	162,894
Restricted cash	1,062	1,521
Investment in non-marketable equity securities ($0 and $13,921 with a related party)	9,700	20,510
Right-of-use assets - Operating leases, net	13,137	39,263
Property and equipment, net	15,487	22,614
Goodwill	2,463	3,241
Other non-current assets	1,246	350
Total assets	136,561	250,393
Current liabilities:
Accounts payable	5,947	3,246
Accrued compensation	11,246	11,453
Other accrued liabilities	4,735	15,279
Current portion of lease obligations - Operating leases	10,121	13,728
Deferred revenue	3,781	5,360
Total current liabilities	35,830	49,066
Deferred revenue, net of current portion	640	16,881
Long-term lease obligations - Operating leases	12,243	38,278
Other long-term liabilities	1,233	1,371
Total liabilities	49,946	105,596
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value per share; 200,000 shares authorized; 69,905 and 65,811 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	7	6
Additional paid-in capital	584,138	566,081
Accumulated deficit	(497,530)	(421,290)
Total stockholders’ equity	86,615	144,797
Total liabilities and stockholders’ equity	$ 136,561	$ 250,393

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with NestlÃƒÂ© Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CEO	Dr. Stephen George Dilly MBBS, Ph.D.
WEBSITE	codexis.com
INDUSTRY	Biotechnology
EMPLOYEES	248

Codexis Inc Frequently Asked Questions

What is the ticker symbol for Codexis Inc? What does CDXS stand for in stocks?

CDXS is the stock ticker symbol of Codexis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Codexis Inc (CDXS)?

As of Tue Apr 23 2024, market cap of Codexis Inc is 203.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers. The fair value of Codexis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Codexis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Codexis Inc a good stock to buy?

The fair value guage provides a quick view whether CDXS is over valued or under valued. Whether Codexis Inc is cheap or expensive depends on the assumptions which impact Codexis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXS.

What is Codexis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, CDXS's PE ratio (Price to Earnings) is -2.67 and Price to Sales (PS) ratio is 2.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Codexis Inc's stock?

In the past 10 years, Codexis Inc has provided 0.054 (multiply by 100 for percentage) rate of return.